Diagnosis: Novel prognostic biomarkers in hepatocellular carcinoma

Nature Reviews Gastroenterology and Hepatology

Volumn 9, Issue 12, 2012, Pages 691-692

  Pang, Roberta W C ^a   Poon, Ronnie T P ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; HUMAN; IMMUNE RESPONSE; LIVER CELL CARCINOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; TUMOR ESCAPE;

ANTINEOPLASTIC AGENTS; C-REACTIVE PROTEIN; CARCINOMA, HEPATOCELLULAR; HUMANS; INTERLEUKIN-6; LIVER NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84870591777     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2012.208     Document Type: Article

References (10)

1. Sieghart, W. et al. A single determination of C reactive protein at the time of diagnosis predicts long-Term outcome of hepatocellular carcinoma. Hepatology http://dx.doi.org/10.1002/hep.26057.
2. Fu, J. et al. The impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology http://dx.doi.org/10.1002/hep.26054
3. Hashimoto, K. et al. The impact of preoperative serum C reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 103, 1856-1864 (2005). (Pubitemid 40563258)
4. An, H. J. et al. Serum C reactive protein is a useful biomarker to predict outcomes after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. http://dx.doi.org/ 10.1002/lt.23512.
5. Jang, J. W. et al. Serum interleukin 6 and C reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine http://dx.doi.org/10. 1016/j.cyto.2012.07.117.
6. Fu, J. et al. Increased regulatory T cells correlate with CD8 T cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132, 2328-2339 (2007). (Pubitemid 46890865)
7. Zhou, J. et al. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int. J. Cancer 125, 1640-1648 (2009).
8. Pedroza-Gonzalez, A. et al. Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology http://dx.doi.org/10.1002/hep.26013.
9. Greten, T. F. et al. Low-Dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-Specific CD4+ T cell responses in patients with advanced HCC. J. Immunother. 33, 211-218 (2010).
10. Pang, R. W. et al. Biology of hepatocellular carcinoma. Ann. Surg. Oncol. 15, 962-971 (2008).